Drug Profile
Arfolitixorin - Isofol Medical
Alternative Names: 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; [6R]-5,10-methylene-THF acid; Arfolitixorin; Arfolitixorin hemisulfate; ISO-901; Modufolin; Modulfolin; SP-05Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Merck Eprova
- Developer Isofol Medical; Oncosyne
- Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
- Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer
- Phase II Osteosarcoma
- Phase I/II Liver metastases; Rectal cancer
- Preclinical Cancer
Most Recent Events
- 28 Dec 2023 Isofol Medical plans a complementary studies of arfolitixorin's effect on organoids in the first quarter of 2024
- 05 Oct 2023 Isofol Medical completes the phase-I/II Modelle-001 trial in Liver metastases (Combination therapy, In adults, In the elderly, Late-stage disease) in Sweden (IV) (NCT04126655)
- 04 Oct 2023 Safety and efficacy data from a phase I/II Modelle-001 trial in Liver metastases presented at the Folate Receptor Society’s 8th International Symposium (FRS)